- Home
- RVNC
as 01-21-2025 4:00pm EST
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | 320.5M | IPO Year: | 2014 |
| Target Price: | $7.78 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $7.56 | Next Earning Date: | 02-26-2025 |
| Revenue: | $256,945,000 | Revenue Growth: | 25.82% |
| Revenue Growth (this year): | 11.28% | Revenue Growth (next year): | 27.21% |
Stock Insider Trading Activity of Revance Therapeutics Inc. (RVNC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hollander David | RVNC | CMO & Global Therapeutics Lead | Nov 18 '24 | Sell | $4.17 | 3,908 | $16,296.36 | 104,945 |
Latest Revance Therapeutics Inc. News
RVNC Breaking Stock News: Dive into RVNC Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
MT Newswires
5 days ago
Revance Rallies after Crown Labs Boosts Buyout Offer
PR Newswire
9 days ago
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
MT Newswires
16 days ago
Sector Update: Health Care Stocks Rise in Afternoon Trading
MT Newswires
16 days ago
Sector Update: Health Care
MT Newswires
16 days ago
Teoxane Offers $3.60 per Share to Acquire Revance Therapeutics, Topping Prior Crown Labs Bid
PR Newswire
16 days ago
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
TipRanks
a month ago
Revance receives acquisition offer from Crown Laboratories for $3.10 per share
Compare RVNC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVNC Revance Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.